Sign inJoin waitlistJoin the waitlist

Barbara O'Brien

Director, Brain Metastases and Leptomeningeal Disease Program · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

Brain Metastases and Leptomeningeal Disease Program · University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
2012–2014
Neurology
University of Connecticut School of Medicine
2009–2012
Preliminary Internal Medicine
University of Connecticut School of Medicine
2008–2009
Doctor of Medicine
2004–2008

Research

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Nature Medicine · 2019 · 1,142 citations
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages
Neuro-Oncology · 2020 · 150 citations
Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma
Neuro-Oncology Advances · 2022 · 79 citations

John de Groot
15 papers
Amy Heimberger
8 papers
Jason Huse
8 papers
Monica Loghin
8 papers
Nazanin Majd
8 papers · 1 as a fellow
Sherise Ferguson
8 papers
Marta Penas-Prado
7 papers
Carlos Matsuoka
6 papers
Ganesh Rao
6 papers
Gregory Fuller
6 papers
Ian McCutcheon
6 papers
RS
Raymond Sawaya
6 papers

Clinical trials

Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology
Principal investigator · Recruiting
M.D. Anderson Cancer Center
2020–2026
Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
Principal investigator · Terminated · Phase 2
M.D. Anderson Cancer Center
2017–2021
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
Principal investigator · Completed · Phase 2
Kintara Therapeutics, Inc.
2017–2024
Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
Principal investigator · Completed · Phase 2
Arog Pharmaceuticals, Inc.
2016–2020